Latest Oncology News

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

September 19th 2021

Antonia DePace

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.

Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19th 2021

Kyle Doherty

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

September 19th 2021

Gina Mauro

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab Demonstrates Notable Activity in Recurrent/Metastatic Cervical Cancer

Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab Demonstrates Notable Activity in Recurrent/Metastatic Cervical Cancer

September 19th 2021

Caroline Seymour

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

September 19th 2021

Conor Killmurray

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Latest Oncology Videos

All Oncology News

Precision Medicine Approaches Evolving With CDK4/6, PI3K Inhibitors in HR+ Breast Cancer

February 21st 2020

Brittany Cote

Sara Tolaney, MD, MPH, reflects on the encouraging findings observed with CDK4/6 inhibitors in combination with endocrine therapy in the treatment of patients with hormone receptor-positive, HER2-negative breast cancer.

Targeted Approaches Under Exploration in Peripheral T-Cell Lymphoma

February 21st 2020

Caroline Seymour

Aaron Goodman, MD, discusses recent changes to the frontline treatment of patients with peripheral T-cell lymphoma and the challenges of targeting T-cell lymphoma.

Dr. Kumar on the Role of Stem Cell Mobilization in Multiple Myeloma

February 21st 2020

Shaji K. Kumar, MD

Shaji K. Kumar, MD, discusses the role of stem cell mobilization in multiple myeloma. This is important in patients with myeloma who are eligible for stem cell transplantation.

Dr. Armstrong on the Rationale of the PROPHECY Trial in mCRPC

February 21st 2020

Andrew J. Armstrong, MD

Andrew J. Armstrong, MD, discusses the rationale of the PROPHECY trial in metastatic castration-resistant prostate cancer.

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

February 21st 2020

Christina Tan, MD, MPH

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Dr. Heyman on Frontline Treatment Options in Follicular Lymphoma

February 21st 2020

Benjamin Heyman, MD

Benjamin Heyman, MD, discusses frontline treatment options for patients with follicular lymphoma.

Dr. Kuykendall on Toxicity Profiles of Ruxolitinib and Fedratinib in Myelofibrosis

February 21st 2020

Andrew T. Kuykendall, M

Andrew T. Kuykendall, MD, discusses the toxicity profiles of ruxolitinib and fedratinib in myelofibrosis.

Dr. Kremyanskaya on Responses With CPI-0610 in Patients With Myelofibrosis

February 21st 2020

Marina Kremyanskaya, MD

Marina Kremyanskaya, MD, PhD, discusses responses with CPI-0610 in patients with myelofibrosis.

Dr. Garcia on the Role of Navitoclax in Myelofibrosis

February 21st 2020

Jacqueline S. Garcia, MD

Jacqueline S. Garcia, MD,discusses how navitoclax differs from other agents in primary or secondary myelofibrosis.

Dr. Danilov on ELEVATE-TN Trial Results in CLL

February 21st 2020

Alexey V. Danilov, MD, PhD

Alexey V. Danilov, MD, PhD, discusses the findings of the phase III ELEVATE-TN trial in treatment-naïve patients with chronic lymphocytic leukemia.

Adjuvant Ipilimumab Shows Early Activity in Advanced Cervical Cancer

February 21st 2020

Nichole Tucker

Immune checkpoint blockade with ipilimumab, combined with radiation therapy, is tolerable and effective in patients with node-positive, stage Ib2 to IV cervical cancer.

Ruxolitinib Efficacy in Chronic GVHD Highlighted Across Age Groups

February 21st 2020

Audrey Sternberg

Ruxolitinib is an effective and well-tolerated treatment in the refractory setting for patients with chronic graft-versus-host disease, regardless of age.

Dr. Fendler on Clinical Need for 68GA-PSMA-11 PET in Prostate Cancer

February 21st 2020

Wolfgang Fendler, MD

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the clinical need for 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer.

Dr. Emens on Combining Checkpoint Inhibitors With PARP Inhibitors in Ovarian Cancer

February 21st 2020

Leisha A. Emens, MD, PhD

Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.

Dr. Cercek on Targeted Strategies in BRAF-Mutant mCRC

February 21st 2020

Andrea Cercek, MD

Andrea Cercek, MD, discusses targeted strategies in BRAF-mutant metastatic colorectal cancer.

See All News